CareDx (CDNA) has drawn fresh attention after recent share price moves, with the stock last closing at US$50.88. Investors are reassessing what the company’s transplant focused testing and software portfolio might imply for valuation.
Recent trading has built on that momentum, with a 1 day share price return of 2.05% and a 30 day share price return of 8.97%. The 90 day share price return of 123.65% and 1 year total shareholder return of 281.41% suggest strong positive sentiment around CareDx’s prospects.
Scan the transplant and biotech space with momentum in mind, and see how CareDx compares with a hand picked 17 high quality undiscovered gems.
CareDx now pairs a focused transplant testing business with a share price that has already moved sharply. The next step is to see whether the current US$50.88 price still reflects that strength or now runs ahead of it.
Most Popular Narrative: 2.8% Undervalued
The most followed CareDx narrative pegs fair value at $52.33, just above the last close at $50.88, which keeps attention firmly on the detailed forecasts behind that gap.
The steady double-digit growth in testing volumes, particularly with the expansion of surveillance protocols for kidney, heart, and lung transplants, suggests ongoing market penetration and growing demand for CareDx's core testing services, reflecting the global rise in organ transplants and chronic disease, which is likely to drive future revenue and topline growth.
Curious what has to happen for CareDx to earn that valuation? The narrative leans on specific revenue growth, margin shifts, and a punchy future earnings multiple. The mix of rising testing volumes, changing profitability, and a much higher implied P/E is doing the heavy lifting in this model. The full narrative lays out exactly which assumptions need to hold and how they tie back to that $52.33 figure.
Result: Fair Value of $52.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors still need to weigh Medicare reimbursement uncertainty and the reliance on AlloSure and HeartCare, where any shift in coverage or volumes could quickly challenge this narrative.
Find out about the key risks to this CareDx narrative.
Another View on CareDx Valuation
The SWS DCF model paints a much stronger picture for CareDx. On that approach, the estimated future cash flow value is $92.87 per share, compared with the current price of $50.88, which points to a large undervaluation. If those cash flow assumptions hold, how comfortable are you with the gap between value and price?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With sentiment on CareDx split between caution and optimism, investors may want to review the underlying data promptly, consider both perspectives, and assess the 2 key rewards and 4 important warning signs.
Looking for more investment ideas beyond CareDx?
If you want a fuller watchlist alongside CareDx, use the Simply Wall St Screener to uncover fresh opportunities that match your style and risk comfort.
- Spot potential mispricing early and review a curated 17 high quality undiscovered gems that might not yet be widely followed.
- Strengthen your portfolio foundation by checking a list of solid balance sheet and fundamentals (53 results) that can help anchor returns in tougher markets.
- Add more income options by scanning a focused 11 dividend fortresses that aims for yield without ignoring balance sheet strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com